CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Clinical trial NCT02675946 · UNKNOWN
Trial details
- NCT number
- NCT02675946
- Sponsor
- Curegenix Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-01
- Primary completion
- 2023-03-01
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.